Beta-Lactam Drugs Market: Increase in prevalence of infectious diseases such as MRSA to drive the market
Albany NY, United States: Beta-lactams are antibacterial drugs that possess the basic characteristic of inhibition of bacterial cell wall synthesis. All Beta-lactams possess similar chemistry, with the exception of alkyl groups that bind to the penicillin binding proteins (PBP) located in bacterial cell walls, thereby inhibiting synthesis and cell death. Pathogenic bacteria are responsible for various infectious diseases and affect billions of individuals globally. Majority of these include pneumonia, impetigo, and urinary tract infections. Some of the widely prescribed drugs in this class include amoxicillin, ampicillin, piperacillin, ticarcillin, imipenem, doripenem, meropenem, ertapenem, cefadroxil, cefalexin, ceftaroline, cefuroxime, cefaclor, ceftriaxone, cefditoren, ceftazidime, and others.
Request a report brochure to gain comprehensive insights at: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33872
Major drivers of the global Beta-lactam drugs market include increase in prevalence of infectious diseases such as MRSA, tuberculosis, pneumonia, and clostridium difficile infections; rise in multidrug-resistant bacterial strains, aging population, and demand for effective and affordable treatments for bacterial infections. Prevalence of infectious diseases is increasing across the globe and is the highest in low to middle income countries. Beta Multidrug-resistant bacterial strains have evolved due to increased usage of Beta-lactam drugs. This provides scope for new innovative drugs and drug combinations. Moreover, aging population in several developed countries is likely to boost market growth, because elderly people have lower immunity and are more prone to infectious diseases. Increase in demand for affordable and effective drugs in the emerging markets is also projected to drive the market during the forecast period.
According to World Health Organization (WHO) estimates, pneumonia accounts for over 1.1 million deaths of children below five years of age each year, which is more than the number of deaths occurring from AIDS, tuberculosis, and malaria (in the same age group) combined. Other data published by the WHO states that tuberculosis affected over 9 million individuals (across all age groups) globally in 2013, of these 1.5 million individuals died. Furthermore, over 0.3 million gonorrhea cases were recorded in 2012 in the U.S. alone. Increase in prevalence of numerous infectious diseases, rise in demand for effective and affordable generic drugs, and potential pipeline drugs that are in late stage (phase III) clinical trials are anticipated to fuel the growth of the market during the forecast period. However, patent expiry of leading branded formulations such as Doribax (June 2015), Cayston (2017), and Teflaro (2018) is a major factor expected to restrain the market. Moreover, a large number of generic Beta-lactam drugs are available are expected to hamper the growth of the market. Continuous innovation and rising incidence of new infectious diseases provide growth opportunities in the Beta-lactam drugs market. The global Beta-lactam drugs market can be segmented based on antibiotic type, distribution channel, and region. In terms of antibiotic type, the market can be classified into penicillin, cephalosporin, carbapenem, and monobactum. Based on distribution channel, the global Beta-lactam drugs market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=33872
Geographically, the global Beta-lactam drugs market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. Asia Pacific held the largest market share in 2016. The Beta-lactam drugs market in this region is highly fragmented, with large number of companies producing branded and generic versions of Beta-lactam drugs. Additionally, rise in prevalence of bacterial infection and increase in government initiatives that appear to be moving toward shorter periods of patent exclusivity for new drug applications are factors attributed to Asia Pacific’s dominance of the market. Presence of large population and growing patient awareness are other factors propelling the market in Asia Pacific. Moreover, increasing geriatric population that is more prone to bacterial infections triggered due to low immunity would consequently increase the uptake of Beta-lactam drugs. North America was the second largest market for Beta-lactam drugs in terms of revenue in 2016. Rise in incidence of bacterial infections is one of the major factors driving the Beta-lactam drugs market in North America, as increasing multidrug-resistant bacterial infections is boosting the development of new anti-infective drugs. Increase in incidence of gram negative bacteria in North America is another major factor attributed to the dominance of the region in the Beta-lactam drugs market.
For any Queries Related with the Report, Ask an Analyst: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=33872
Key players operating in the global Beta-lactam drugs market are GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Cubist Pharmaceuticals (Subsidiary of Merck & Co), Eli Lilly and Company, and Shionogi, Inc., among others.
More Trending Reports by Transparency Market Research:
Epoetin Beta Therapeutics Market: Erythropoietin is a hormone released from the kidneys. Erythropoietin protein is responsible for the development of red blood cells (RBCs) in the body. Increase in the number of RBCs raises the level of hemoglobin in the blood, which is the substance responsible for transport of oxygen to every part of the body. Epoetin beta is one of the three erythropoiesis-stimulating agents available in the epoetin beta therapeutics market.
Beta-2 Microglobulin Testing Market: Beta-2 microglobulin is a protein of major histocompatibility complex class I molecules, which is used as tumor marker for certain blood cancers. It is present on all nucleated cells. The beta-2 microglobulin is tested in plasma, serum, or urine samples. The beta-2 microglobulin level in the sample helps detect disease activity; for example, low level of beta-2 microglobulin in serum indicates less disease activity, while high levels indicate higher disease activity.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453